Table 2.
Comparison of secondary outcome measures across treatment arms.
| Secondary outcome measure | GC80 | GC50 | GCb6 | p-value |
|---|---|---|---|---|
| Best overall response rate | ||||
| Number (%) of patients with reported CR or PR | 132/456 (29%) | 92/454 (20%) | 123/453 (27%) | 0.007 |
| Dose intensity for platinum | ||||
| N | 423 | 430 | 406 | |
| Median | 94% | 98% | 83% | <0.0001 |
| Interquartile range | 81%–99% | 90%–100% | 72%–97% | |
| Range | 22%–116% | 19%–113% | 19%–118% | |
| Number (%) of patients ≥90% | 256 (61%) | 327 (76%) | 146 (36%) | |
| Dose intensity for gemcitabine | ||||
| N | 419 | 429 | 423 | |
| Median | 87% | 94% | 80% | |
| Interquartile range | 74–98% | 83–99% | 68–94% | <0.0001 |
| Range | 40–116% | 43–107% | 32–106% | |
| Number (%) of patients ≥90% | 192 (46%) | 260 (61%) | 127 (30%) | |
| Proportion of chemotherapy delivery days as an outpatient | ||||
| N | 441 | 444 | 439 | |
| Median | 87.5% | 100% | 100% | <0.0001 |
| Number (%) of patients 100% | 207 (47%) | 246 (55%) | 281 (64%) | |
| Adverse events | ||||
| Number (%) of patients with at least 1 grade 3 or 4 adverse event reported during treatment | 190/441 (43%) | 133/444 (30%) | 263/439 (60%) | <0.0001 |
CR, complete response; PR, partial response.